Perspective on medication decisions following remission from first-episode psychosis.

Christy L M Hui, Bertha S T Lam, Edwin H M Lee, Sherry K W Chan, W C Chang, Y N Suen, Eric Y H Chen

Schizophrenia research 2020 Nov

filter terms:

While antipsychotics (APs) could provide rapid relief of positive symptoms in psychotic disorders, their usage is often associated with side effects, stigma and inconveniences. For these and other reasons, many psychosis patients, particularly those of first-episode psychosis (FEP) in remission, wish to discontinue maintenance treatment. The current review aims to discuss the strategies of AP treatment following remission from FEP, with particular emphasis on the evaluation of outcomes following AP discontinuation. Upon review of relevant literature, three potential strategies are put forth for treatment-responsive, remitted FEP patients: a) life-long maintenance treatment, b) AP discontinuation during second year of treatment, or c) AP discontinuation after three years of treatment. In theory, the first strategy presents the safest option for maximal symptom control. However, a rigorous RCT indicates that if AP discontinuation is to be attempted, the third strategy best prevents poor long-term clinical outcomes. Further data is needed to address the costs and benefits of each treatment strategy, compare AP-free patients with those on different types of APs, as well as explore even longer-term outcomes. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Christy L M Hui, Bertha S T Lam, Edwin H M Lee, Sherry K W Chan, W C Chang, Y N Suen, Eric Y H Chen. Perspective on medication decisions following remission from first-episode psychosis. Schizophrenia research. 2020 Nov;225:82-89